CU Anschutz Cancer Center Oncologist Chris Lieu, MD, underscores how daraxonrasib targets the KRAS mutation in pancreatic cancer, improving survival while potentially reducing side effects.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045